Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes.

Sallman DA, McLemore AF, Komrokji R, Elmariah H, Kuykendall AT, Bejanyan N, Chan O, Faramand R, Pidala J, Yoder SJ, Perez L, Nishihori T, Padron E, Fernandez H, Lancet JE, Mishra A

Open source

DOI: 10.1182/bloodadvances.2025017742
Published: 2026 Feb 24
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025017742,
  title = {Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes.},
  author = {Sallman DA and McLemore AF and Komrokji R and Elmariah H and Kuykendall AT and Bejanyan N and Chan O and Faramand R and Pidala J and Yoder SJ and Perez L and Nishihori T and Padron E and Fernandez H and Lancet JE and Mishra A},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025017742},
  url = {https://doi.org/10.1182/bloodadvances.2025017742}
}

RIS

TY  - JOUR
TI  - Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes.
AU  - Sallman DA
AU  - McLemore AF
AU  - Komrokji R
AU  - Elmariah H
AU  - Kuykendall AT
AU  - Bejanyan N
AU  - Chan O
AU  - Faramand R
AU  - Pidala J
AU  - Yoder SJ
AU  - Perez L
AU  - Nishihori T
AU  - Padron E
AU  - Fernandez H
AU  - Lancet JE
AU  - Mishra A
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025017742
UR  - https://doi.org/10.1182/bloodadvances.2025017742
ER  -

APA

DA, S., AF, M., R, K., H, E., AT, K., N, B., O, C., R, F., J, P., SJ, Y., L, P., T, N., E, P., H, F., JE, L., & A, M. (2026). Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes.. Blood advances. https://doi.org/10.1182/bloodadvances.2025017742

Source records

pubmed · retrieved 2026-09-26T05:07:28.655Z